Effects of losartan and valsartan on left ventricular hypertrophy and function in essential hypertension

Advances in Therapy

Volumn 21, Issue 2, 2004, Pages 76-86

  Picca, Maurizio ^a,b   Agozzino, Francesco ^a   Pelosi, Giancarlo ^a  

^a FATEBENEFRATELLI HOSPITAL   (Italy)

^b Melloni Hospital   (Italy)

Author keywords

Cardiac hypertrophy; Hypertension

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; LOSARTAN; VALSARTAN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOPPLER ECHOCARDIOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ESSENTIAL HYPERTENSION; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; SYSTOLIC BLOOD PRESSURE;

EID: 3343008717     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02850335     Document Type: Article

References (30)

1. Koren MJ, Devereux RB, Casale PN, et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991;114:345-352.
2. de Simone G, Devereux RB, Koren MJ, et al. Midwall left ventricular mechanics. An independent predictor of cardiovascular risk in arterial hypertension. Circulation. 1996;93:259-265.
3. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hyperten. 1992;5:95-110.
4. Hernandez R, Sana-Canache B, Velasco M, et al. Angiotensin II receptor antagonists role in arterial hypertension. J Hum Hypertens. 2002;16(suppl 1):S93-S99.
5. Fyhrquist F, Metsarinne K, Tikkanen I. Role of angiotensin II in blood pressure regulation and the pathophysiology of cardiovascular disorders. J Hum Hypertens. 1995;(suppl 5):S19-S24.
6. Yamada T, Horiuchi M, Dzau VJ. Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci USA. 1996;93:156-160.
7. Cheung B. Increased left ventricular mass after losartan treatment. Lancet. 1997;349:1743-1744.
8. Himmelmann A, Svensson A, Bergbrant A, et al. Long-term effects of losartan on blood pressure and left ventricular structure in essential hypertension. J Hum Hypertens. 1996;10:729-734.
9. Tedesco MA, Ratti G, Aquino D, et al. Effect of losartan on hypertension and left ventricular mass: a long-term study. J Hum Hypertens. 1998;12:493-495.
10. Thurmann PA, Kenedi P, Schmidt A, et al. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation. 1998;98:2037-2042.
11. Sahn DJ, de Maria A, Kisslo J, et al. Standardization of the American Society of Echocardiography regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978;58:1072-1083.
12. Teichholz LE, Krevient T, Herman PV, et al. Problems in echocardiographic volume determinations. Echocardiographic-angiographic correlations in the presence or absence of asinergy. Am J Cardiol. 1976;37:7-11.
13. Devereux RB, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450-458.
14. de Simone G, Daniels RS, Devereux RB, et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and the impact of overweight. J Am Coll Cardiol. 1992;20:1251-1260.
15. Reichek N, Devereux RB. Reliable estimation of peak left ventricular systolic pressure by M-mode echographic-determined end-diastolic wall thickness: identification of severe valvular aortic stenosis in adult patients. Am Heart J. 1982;103:202-203.
16. Ganau A, Devereux RB, Casale PN, et al. Patterns of left ventricular and geometric remodeling in essential hypertension. J Am Coll Cardiol. 1996;19:259-265.
17. Gaash WH, Zile MR, Hosino PK, et al. Stress-shortening relation and myocardial blood flow in compensated and failing canine hearts with pressure-overload hypertrophy. Circulation. 1989;79:872-883.
18. de Simone G, Devereux RB, Roman MJ, et al. Assessment of left ventricular function by the midwall fractional shortening-end-systolic stress relation in human hypertension. J Am Coll Cardiol. 1994;23:1444-1451.
19. DeMaria PN, Wisenbough TW, Smith MD, et al. Doppler echocardiographic evaluation of diastolic dysfunction. Circulation. 1991;84:288-295.
20. Fouad FM, Nakashima Y, Tarazi RC, et al. Reversal of left ventricular hypertrophy with methyldopa. Am J Cardiol. 1982;49:795-801.
21. Dunn FG, Ventura HO, Messerli FH, et al. Time course of regression of left ventricular hypertrophy in hypertensive patients treated with atenolol. Circulation. 1987;76:254-258.
22. deSimone G, Costantino G, Soro S, et al. Effects of nicardipine on left ventricular hemodynamic patterns in systemic hypertension. Am J Hypertens. 1989;2:139-145.
23. Saragoza MA, Portela JE, Abren P, et al. Regression of left ventricular hypertrophy in the short-term treatment of hypertension with nicardipine. Am J Hypertens. 1991;4(suppl):1885-1905.
24. Fouad FM, Tarazi RC, Bravo EL. Hemodynamic and cardiac effects of enalapril. Hypertension. 1983;1(suppl 1):135-142.
25. Nakashima Y, Fouad FM, Tarazi RC. Regression of left ventricular hypertrophy from systemic hypertension by enalapril. Am J Cardiol. 1984;53:1044-1049.
26. Dahlof B. Effects of angiotensin II blockade on cardiac hypertrophy and remodeling: a review. J Hum Hypertens. 1997;(suppl 2):S9-S17.
27. Liebson PR, Savage DD. Echocardiography: a review. II. Echocardiographic studies on the effects of antihypertensive agents on left ventricular mass and function. Echocardiography. 1987;4:215-249.
28. Fayerberg B, Beglund A, Andersson OK, et al. Cardiovascular effects of weight reduction versus antihypertensive drug treatment: a comparative, randomized 1-year study of obese men with mild hypertension. J Hypertens. 1991;9:431-439.
29. Gradman AH. AT (1) - receptor blockers: differences that matter. J Hum Hypertens. 2002;16(suppl 3): S9-S16.
30. 1-receptor blockers valsartan and losartan quantified by renal interstitial fluid cGMP. J Hypertens. 2002;20:1-6.